Table 1.
Clinical and epidemiological data of 73 patients with sporotrichosis treated with amphotericin B at the INI/FIOCRUZ, Rio de Janeiro, Brazil, between 1998 and 2018.
| Variable | Status | N = 73 |
|---|---|---|
| Sex | Male | 53 (72.6%) |
| Female | 20 (27.4%) | |
| Age | 46.06 [16.18, 83.95] d | |
| Skin color a | Non-white | 54 (75.0%) |
| White | 18 (25.0%) | |
| Schooling b | 1–7 years | 35 (58.3%) |
| >7 years | 21 (35.0%) | |
| Non-literate | 4 (6.7%) | |
| HIV | 38 (52.1%) | |
| Alcoholism | 21 (28.8%) | |
| Diabetes | 15 (20.5%) | |
| Tuberculosis | 13 (17.8%) | |
| Corticosteroid use | 6 (8.2%) | |
| Clinical presentation | Disseminated | 54 (73.9%) |
| Unifocal extracutaneous | 8 (11.0%) | |
| Cutaneous disseminated | 8 (11.0%) | |
| Cutaneous localized | 3 (4.1%) | |
| Affected organ c | Skin | 72 (98.6%) |
| Osteoarticular | 47 (64.4%) | |
| Upper airways | 31 (42.5%) | |
| Central nervous system | 15 (20.5%) | |
| Ocular | 9 (12.3%) | |
| Lungs | 6 (8.2%) | |
| Deoxycholate total dose (mg) | 750.00 [50.00, 11,250.00] e | |
| Lipid complex total dose (mg) | 4500.00 [200.00, 14,700.00] e | |
| Total treatment duration (days) | 696.00 [1.00, 4017.00] e | |
| Outcome | Cure | 38 (52.1%) |
| Death due to sporotrichosis | 16 (21.9%) | |
| Death due to other causes | 7 (9.6%) | |
| Loss to follow-up | 6 (8.2%) | |
| Still under treatment | 6 (8.2%) | |
a Missing data (N = 1); b Missing data (N = 13); c Several patients had more than one affected organ; d Mean and range; e Median and range.